Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 14/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 13/20 | 0.41 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ITGB6 | P18564 | 4/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.32 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.32 |
| ▸ | FABP6 | P51161 | 1/20 | 0.32 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.32 |
| ▸ | FEN1 | P39748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6261287 | 0.91 | ITGAV (0.37) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL14476045 | 0.87 | GRM5 (0.39) | ITGAVITGB3ITGB1ITGA5GRM5 | |
| SCHEMBL26538782 | 0.84 | ITGB3 (0.39) | ITGAVITGB3ITGB1ITGA5GRM5 | |
| SCHEMBL24440037 | 0.84 | ITGAV (0.39) | ITGAVITGB3ITGB1ITGA5GRM5 | |
| SCHEMBL8172614 | 0.82 | ITGAV (0.38) | ITGAVITGB3ITGB1ITGA5GRM5 | |
| SCHEMBL26457526 | 0.81 | ALDH1A1 (0.40) | ITGAVITGB3ITGB1ITGA5GRM5 | |
| SCHEMBL12807108 | 0.81 | KCNH2 (0.42) | ITGAVITGB3ITGB1ITGA5GRM5 | |
| SCHEMBL6106216 | 0.79 | ITGB3 (0.52) | ITGAVITGB3ITGB1ITGA5ITGB6 | |
| SCHEMBL8039387 | 0.79 | ITGAV (0.40) | ITGAVITGB3ITGB1ITGA5GRM5 | |
| SCHEMBL8325969 | 0.79 | ITGAV (0.40) | ITGAVITGB3ITGB1ITGA5GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425010-B1 | SUBSTITUTED INDOLES AND THEIR USE AS INTEGRIN ANTAGONISTS | ORTHO MCNEIL PHARM INC (US) | 2011-10-26 | — | — | EP | disclosed |
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | LU TIANBO | 2007-09-20 | — | — | US | disclosed |
| US-7241789-B2 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICAL, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-6949578-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-09-22 | — | — | US | disclosed |
| US-6921767-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION (US) | 2005-07-26 | — | — | US | disclosed |
| US-6900232-B2 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION (US) | 2005-05-31 | — | — | US | disclosed |
| US-6855722-B2 | Substituted indoles and their use as integrin antagonists | DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1501830-A1 | 7-ARYL-3,9-DIAZABICYCLO[3.3.1]NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | Actelion Pharmaceuticals Ltd. (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2004-12-23 | — | — | US | disclosed |
| WO-2004058254-A1 | HETEROARYLALKANOIC ACIDS AS INTEGRIN RECEPTOR ANTAGONISTS | PHARMACIA CORPORATION (US) | 2004-07-15 | — | — | WO | disclosed |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | PHARMACIA CORPORATION | 2004-03-04 | — | — | US | disclosed |
| WO-2003093267-A1 | 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES | ACTELION PHARMACEUTICALS LTD (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-11-14 | — | — | US | disclosed |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | PHARMACIA CORPORATION | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219233-A1 | Antitumor, antiinflammatory, antiarthritic agents, treating metastasis, restenosis, osteoporosis, macular degeneration, and diabetic retinopathy; 7-(2-{1-[1-(3-Benzyloxy-phenyl)-2-ethoxycarbonyl-vinyl]-1H-indol-5-yloxy}-ethyl)-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester | ITGA5, ADGRE5, ITGAV | ITGAV 3/4885ITGB3 10/4885ITGB1 5/4885 |
| US-20040043988-A1 | Cycloalkyl alkanoic acids as intergrin receptor antagonists | ADGRE5, ITGA5, ADGRF1 | ITGAV 7/4885ITGB3 5/4885ITGB1 8/4885 |
| US-20050209225-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | ITGAV 1/4885ITGB3 6/4885ITGB1 5/4885 |
| US-20040092538-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives | ITGA5, ITGB5, ITGB3 | ITGAV 6/4885ITGB3 3/4885ITGB1 5/4885 |
| US-20040259869-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | ITGAV 7/4885ITGB3 3/4885ITGB1 6/4885 |
| US-20020169200-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGAL, ITGA5 | ITGAV 1/4885ITGB3 10/4885ITGB1 4/4885 |
| US-20050250771-A1 | Substituted indoles and their use as integrin antagonists | ITGAV, ITGA5, ITGB5 | ITGAV 1/4885ITGB3 6/4885ITGB1 5/4885 |
| US-20020077321-A1 | Cycloalkyl alkanoic acids as integrin receptor antagonists | ITGA5, ITGB5, ITGB3 | ITGAV 7/4885ITGB3 3/4885ITGB1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.